Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization
Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization
复制标题
达到无法治疗进展的时间是肝细胞癌患者经动脉化疗栓塞术后总生存期的适当替代终点
DOI：
10.4103/jcrt.jcrt_898_19
复制
发表时间：
2020-04
期刊：
影响因子：
--
通讯作者：
李家平
中科院分区：
文献类型：
--
作者：
王洪雨;李彬;王于;张将;吴艳琴;范文哲;李家平
目的：本研究的目的是确定至进展时间（TTP）或至不可治疗进展时间（TTUP）是否是肝细胞癌（HCC）患者经动脉化疗后总生存期（OS）的适当替代终点。
Aims: The aim of the study was to determine whether the time to progression (TTP) or time to untreatable progression (TTUP) is an appropriate surrogate endpoint for overall survival (OS) in patients with hepatocellular carcinoma (HCC) after transarterial